ClinicalTrials.gg
RecruitingNCT05553236TSELiOTUpdated Jan 26, 2026

Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis

An interventional study of Targeted next-generation sequencing in Drug-resistant Tuberculosis, HIV Coinfection and Cost-Benefit Analysis, sponsored by University of California, San Francisco. Recruiting at 1 site in South Africa. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,500
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.

Planned enrollment
4th of 37
2,500 · median 248
Started
2024
the only one that year
No phase
8 of 46
5 open now
Registered
40th of 46
by date

Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 4th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 40th registered.

Tuberculosis, Multidrug-Resistant

132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.

Browse Tuberculosis, Multidrug-Resistant studies →

Open to participants now

7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, or all of them as a file.
02

Study summary

TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.

03

Conditions studied

  • Drug-resistant Tuberculosis
  • HIV Coinfection
  • Cost-Benefit Analysis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Active RR-TB diagnosed at a study facility during the study period
  2. Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)

Exclusion criteria

Exclusion Criteria:

  1. Patient expects to relocate/move residence outside of the study region
  2. Patient does not agree to participate in the study

In addition, participants later found to have isolates with rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be considered late exclusions.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    Sequencing Intervention in addition to standard of care

    Batched targeted deep sequencing in addition to the locally accepted standard of care drug susceptibility determination of multidrug/extensively drug-resistant tuberculosis (M/XDR-TB)

    Diagnostic Test: Targeted next-generation sequencing

  • No intervention
    Standard of Care

    Locally accepted standard of care which is consistent with the WHO recommendations for the drug susceptibility determination of M/XDR-TB

Interventions

  • Diagnostic testTargeted next-generation sequencing

    During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.

06

What researchers measure

Primary outcomes

  1. Number of participants with prespecified end of treatment outcomes

    The number of participants with each of the following prespecified end of treatment outcomes will be reported: cure, treatment completed, loss to follow up, treatment failure, death, transfer, and still on treatment.

    Time frame: At the anticipated completion of prescribed treatment, up to 18 months

Secondary outcomes

  1. 12-month relapse-free survival

    Length of time after treatment ends that the patient survives without TB recurrence

    Time frame: From completion of prescribed treatment to death or TB recurrence, up to 12 months

  2. Exposure time to ineffective drugs

    Cumulative length of time on individual drugs to which Mtb is found to be resistant, per participant

    Time frame: At the anticipated completion of prescribed treatment, up to 18 months

  3. Number of participants with acquired drug resistance

    Number of participants with M.tuberculosis acquiring additional drug resistance during treatment

    Time frame: At the anticipated completion of prescribed treatment, up to 18 months

  4. Time to effective treatment initiation with three drugs

    Length of time from diagnosis to treatment initiation with at least three effective drugs to which M.tuberculosis is susceptible

    Time frame: From diagnosis to treatment initiation with at least three effective drugs, up to 18 months

  5. Time to effective treatment initiation with four drugs

    Length of time from diagnosis to treatment initiation with at least four effective drugs to which M.tuberculosis is susceptible

    Time frame: From diagnosis to treatment initiation with at least four effective drugs, up to 18 months

  6. Time to culture conversion

    Length of time from diagnosis to stable culture conversion, defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB, up to 9 months

    Time frame: From diagnosis to stable culture conversion, up to 9 months

Other outcomes

  1. Number of participants with clinical uptake of sequencing intervention results

    The number of sequencing intervention results with treatment regimen adjustment where appropriate treatment change is indicated

    Time frame: At the anticipated completion of prescribed treatment, up to 18 months

  2. Cost-effectiveness of the sequencing intervention

    Costs of necessary personnel, consumables, facility, logistics, and per unit tests

    Time frame: At the anticipated completion of prescribed treatment, up to 18 months

07

Study locations

1 of 1 sites recruiting
  • South African National Health Laboratory Service
    Cape Town, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 23, 2022
StartActual
Aug 1, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05553236
Collaborators
University of Stellenbosch, National Health Laboratory Service (NHLS), South Africa, National Institute for Communicable Diseases, South Africa, National Institute of Allergy and Infectious Diseases (NIAID), Find, Translational Genomics Research Institute, University Hospital Heidelberg
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Aug 1, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

John Z Metcalfe, MD, PhD
Contact
john.metcalfe@ucsf.edu
+14152068314
Rob Warren, PhD
Contact
John Z Metcalfe, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion